| dbo:abstract
|
- Drospirenone/ethinylestradiol/levomefolic acid (EE/DRSP/LMF), sold under the brand names Beyaz among others, is a combination of ethinylestradiol (EE), an estrogen, drospirenone (DRSP), a progestogen, antimineralocorticoid, and antiandrogen, and levomefolic acid (LMF), a form of vitamin B9, which is used as a birth control pill to prevent pregnancy in women. The formulation contains folate as the calcium salt of levomefolic acid to lower the risk of complications such as fetal neural tube defects should the medication fail as a form of birth control. EE/DRSP/LMF was approved for use by the U.S. Food and Drug Administration (FDA) on 24 September 2010. (en)
|
| dbo:alternativeName
|
- Beyaz, Safyral, Tydemy (en)
|
| dbo:kegg
| |
| dbo:license
| |
| dbo:medlinePlus
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 9549 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:caption
|
- Ethinylestradiol (en)
- Drospirenone (en)
|
| dbp:chemspiderid
| |
| dbp:class
| |
| dbp:component
|
- Ethinylestradiol (en)
- Drospirenone (en)
- Levomefolic acid (en)
|
| dbp:dailymedid
|
- Drospirenone,_ethinyl estradiol_and_levomefolate_calcium (en)
|
| dbp:image
| |
| dbp:kegg
| |
| dbp:legalStatus
| |
| dbp:licenceUs
| |
| dbp:medlineplus
| |
| dbp:pregnancyUs
| |
| dbp:routesOfAdministration
| |
| dbp:synonyms
|
- EE/DRSP/LMF; EE/DRSP/THF; EE/DRSP/THFA; EE/DRSP/FH4; EE/DRSP/VB9 (en)
|
| dbp:tradename
|
- Beyaz, Safyral, Tydemy (en)
|
| dbp:type
| |
| dbp:verifiedrevid
| |
| dbp:width
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Drospirenone/ethinylestradiol/levomefolic acid (EE/DRSP/LMF), sold under the brand names Beyaz among others, is a combination of ethinylestradiol (EE), an estrogen, drospirenone (DRSP), a progestogen, antimineralocorticoid, and antiandrogen, and levomefolic acid (LMF), a form of vitamin B9, which is used as a birth control pill to prevent pregnancy in women. The formulation contains folate as the calcium salt of levomefolic acid to lower the risk of complications such as fetal neural tube defects should the medication fail as a form of birth control. EE/DRSP/LMF was approved for use by the U.S. Food and Drug Administration (FDA) on 24 September 2010. (en)
|
| rdfs:label
|
- Drospirenone/ethinylestradiol/levomefolic acid (en)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
